Furthermore, treatment with CCX140-B, an antagonist to C–C chemokine receptor 2 which monocyte chemoattractant protein-1 binds to, resulted in a reduction in albumin–creatinine ratio (127), glomerular hypertrophy, and increased podocyte density in experimental diabetes (127). Here, ALB is linked to diabetes mellitus.